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Abstract
Background: Genome-wide association studies have identified 196 high confidence independent signals
associated with breast cancer susceptibility. Variants within these signals frequently fall in distal regulatory DNA
elements that control gene expression.
Results: We designed a Capture Hi-C array to enrich for chromatin interactions between the credible causal
variants and target genes in six human mammary epithelial and breast cancer cell lines. We show that interacting
regions are enriched for open chromatin, histone marks for active enhancers, and transcription factors relevant to
breast biology. We exploit this comprehensive resource to identify candidate target genes at 139 independent
breast cancer risk signals and explore the functional mechanism underlying altered risk at the 12q24 risk region.
Conclusions: Our results demonstrate the power of combining genetics, computational genomics, and molecular
studies to rationalize the identification of key variants and candidate target genes at breast cancer GWAS signals.
Introduction
Breast cancer is known to have an important inherited
component. While rare coding mutations in susceptibil-
ity genes such as BRCA1, BRCA2, and PALB2 confer a
high risk of breast cancer, these account for less than
one quarter of the familial risk [1]. Much of the
remaining heritability is due to the combination of a
large number of common, low-penetrance variants [2,
3]. Genome-wide association studies (GWAS) have been
a powerful tool to identify disease-associated genetic var-
iants, but these studies do not directly address the
underlying biological mechanisms. A combination of
fine-scale mapping and bioinformatic and functional
studies are required to establish this link [4]. The Breast
Cancer Association Consortium (BCAC) and the
Consortium of Investigators of Modifiers of BRCA1/2
(CIMBA) have recently performed large-scale genetic
fine-mapping of 150 breast cancer susceptibility regions
in ~ 217,000 breast cancer cases and controls of Euro-
pean ancestry [5]. Step-wise multinomial logistic regres-
sion analysis identified 196 high confidence independent
risk signals, defined as having association p values < 10−6
after adjusting for other variants. Fachal et al. [5] used
these data to define sets of credible causal variants
(CCVs) for each signal, defined as variants with p values
within 2 orders of magnitude of the top variant.
The majority of CCVs mapped to non-protein-coding
regions of the genome and are enriched at regulatory
DNA elements such as enhancers, silencers, and insula-
tors [2, 5]. It is established that many regulatory ele-
ments are located long distances from their target gene
promoters and that regulation of transcription involves
direct physical interactions brought about by chromatin
looping [6]. Importantly, individual enhancers often loop
to and regulate multiple genes, including protein-coding
and non-coding RNA genes. Adding to the complexity,
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enhancers do not necessarily act on the closest promoter
but can bypass neighboring genes to regulate genes lo-
cated more distally. There is also considerable evidence
that most enhancer-promoter interactions occur in cis
and within chromatin structures called topologically as-
sociating domains (TADs) [7]. TADs are typically several
hundred kilobases to a few megabases in size and are
relatively stable between cell types and in response to
extracellular signals [8, 9].
Various chromatin conformation capture (3C)-based
methods have been developed to map chromatin con-
tacts at a genome-wide level. The basic principle of 3C
involves chromatin fragmentation of formaldehyde-fixed
nuclei (usually by restriction digestion), followed by
ligation of linked DNA fragments, then detection and
quantification of ligation products [10]. One of these
methods, Hi-C, is an unbiased but relatively low-
resolution approach that quantifies interactions between
all possible DNA fragment pairs in the genome [11]. Hi-
C has been used extensively to analyze the three-
dimensional organization of genomes, including the
compartmentalization of chromatin and the position of
TADs [12, 13]. To increase Hi-C resolution, several
groups have developed sequence capture to enrich for
chromosomal interactions involving targeted regions of
interest [14–17]. There are several capture methodolo-
gies, but typically, RNA or DNA oligonucleotide baits
are directed to the ends of targeted DNA fragments to
enrich for ligation events prior to next-generation se-
quencing [18, 19]. Promoter Capture Hi-C (PCHi-C) is
the most widely used approach where baits are designed
to annotated promoters, resulting in a strong enrich-
ment for promoter-anchored interactions [15–17, 20]. A
few post-GWAS studies have also used Region Capture
Hi-C, in which baits target linkage disequilibrium blocks
or restriction fragments containing genetic variants asso-
ciated with the disease of interest [21, 22].
Here, we applied Variant Capture Hi-C (VCHi-C) and
PCHi-C to normal breast and breast cancer cell lines to
generate a catalog of interactomes. We report several
hundred candidate target genes in breast cancer risk re-
gions including some known cancer driver genes but
also many molecular targets not previously implicated in
breast cancer etiology.
Results
VCHi-C and PCHi-C interaction profiling
To enrich for chromatin interactions relevant to breast
cancer risk, we designed two capture arrays, Variant
Capture (VC) and Promoter Capture (PC). The VCHi-C
baits were designed to HindIII fragments that contained
at least 1 CCV, regardless of the CCV regulatory poten-
tial (Fig. 1a [5];). We could design baits to 1432 HindIII
fragments encompassing 6044/7394 CCVs. The PCHi-C
baits were designed to 4045 HindIII fragments contain-
ing 8216 annotated GENCODE v19 promoters within 1
Mb of CCVs at breast cancer risk signals (Fig. 1a). This
dual-capture approach ensured comprehensive coverage
of each risk signal and provided independent validation
of interactions. We performed in situ VCHi-C and
PCHi-C [16, 18] in 2 non-tumorigenic breast cell lines
(B80T5, MCF10A), 2 estrogen receptor-positive (ER+;
MCF7, T47D) breast cancer cell lines, and 2 ER−
(MDAMB231, Hs578T) breast cancer cell lines. Sequen-
cing of both captures produced over 1 billion unique di-
tags involving CCV-containing fragments and annotated
promoters (Additional file 2: Table S1). To assess the ro-
bustness of the approach, each CHi-C experiment was
conducted in 2 biological replicates per cell type. We ob-
served a strong correlation between the replicates, par-
ticularly when captured interaction pairs were within
0.5Mb (Additional file 1: Figure S1a).
We initially used the CHiCAGO pipeline [23] to assign
confidence scores to interactions derived from the
VCHi-C and PCHi-C (Additional file 2: Tables S2, S3).
Principal component analysis (PCA) based on the CHi-
CAGO scores demonstrated concordance for individual
replicates in the VCHi-C and PCHi-C. Consistent with
previous gene expression profiling [24], PCA separated
ER+ breast cancer from normal-like breast or ER− breast
cancer cell lines (Fig. 1b). Using a strict interaction
threshold (CHiCAGO score ≥ 5, intrachromosomal and
interaction distance ≤ 2Mb), we detected on average ~
10,000 VCHi-C and ~ 27,000 PCHi-C high-confidence
interactions per cell type (Fig. 1c and Additional file 2:
Tables S2, S3). The difference in the interaction number
between the captures likely reflects the higher number
of PCHi-C baits. In addition, VCHi-C baits were de-
signed to all possible CCV-containing HindIII fragments,
but some CCVs will be correlated with passenger vari-
ants or function through alternative non-looping mecha-
nisms, such as promoter variants. For the VCHi-C, we
detected a median of 5 variant-interacting regions (VIRs;
Fig. 1a) per bait per cell type, of which 3.6–5.5% inter-
acted with an annotated protein- or non-coding pro-
moter. This CCV-promoter interaction number is
consistent with the assumption that only a small subset
of CCVs from each signal are functional regulatory vari-
ants. Similarly, for the PCHi-C, we detected a median of
5 promoter-interacting regions (PIRs; Fig. 1a) per bait
per cell type, where 2.2–2.7% specifically interacted with
a CCV-containing fragment (Additional file 1: Figure
S1b and Additional file 2: Tables S2, S3). The median
linear distance between interactions from either capture
ranged from 192 to 405 kb (Additional file 1: Figure
S1c), and ~ 70% of the CHi-C interactions occurred
within TAD boundaries. Hierarchical clustering based
on the CHiCAGO scores separated the cell lines based
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on ER status (Fig. 1d), which suggested that ER status me-
diates cell-type specificity of the interactomes. We also ob-
served a positive correlation (Pearson’s r = 0.60–0.84) in
the CHiCAGO scores for interactions detected in both
the VCHi-C and PCHi-C (Additional file 1: Figure S1d),
thus validating our approach.
Interacting regions are enriched for regulatory features,
eQTLs, and CCVs in breast cells
We first annotated CHiCAGO-scored PIRs in each
breast cell type with DNase-seq data derived from a di-
verse panel of cells and tissues as part of the Roadmap
Epigenomics Project [25]. We found PIRs to be enriched
for regions of accessible chromatin in human mammary
epithelial cells (HMEC) (Additional file 1: Figure S2a
and Additional file 2: Table S4). To explore this
observation in additional breast cells, we annotated PIRs
with assay for transposase-accessible chromatin
sequencing (ATAC-seq) peaks in five breast cell lines
(Additional file 2: Table S5) and noted that the
enrichment signals were stronger from PIRs detected in the
matched cell line (Fig. 2a and Additional file 2: Table S4).
We next investigated the epigenetic makeup of PIRs using
ChIP-seq data for histone modifications and other DNA-
binding proteins in human cell lines. PIRs were significantly
enriched for histone marks associated with active enhancers
(H3K27ac and H3K4me1) in the majority of cell lines as
compared to inactive elements which are typically marked
by the polycomb-associated mark H3K27me3 (Fig. 2b and
Additional file 2: Table S4).
Binding sites for several structural proteins with estab-
lished roles in chromatin looping were also enriched in
Fig. 1 VCHi-C and PCHi-C in human breast cell lines. a Schematic of a hypothetical breast cancer risk signal and plausible chromatin interactions.
Chromatin interactions are shown as blue arcs. Genes are depicted as black arrows. CHi-C baits are depicted as gray boxes. CCVs are shown as
red vertical lines. The colored boxes illustrate variant-interacting regions (VIRs) or promoter-interacting regions (PIRs). b Principle component
analysis of the CHiCAGO-scored interactions in VCHi-C or PCHi-C biological replicates. c Distribution of the CHiCAGO-scored interaction number
per bait per cell line (combined biological replicates). d Agglomerative hierarchical clustering for the VCHi-C and PCHi-C in six breast cell lines
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PIRs, including CTCF and the cohesin subunits RAD21
and STAG1 (Additional file 1: Figure S2b and Add-
itional file 2: Table S4), consistent with the role of these
factors in mediating long-range genomic interactions [9,
12]. Associations were also observed for the cistromes of
established breast cancer transcription factors (TFs);
ESR1, FOXA1, and GATA3 [26, 27] (Fig. 2c). Notably,
ESR1 ChIP-seq peaks were observed at 18% of PIRs in
MCF7 cells. Furthermore, the subset of interacting re-
gions with ESR1 binding was significantly enriched for
GATA3 binding (p < 2.2e−16), consistent with the
known role for GATA3 in modulating estrogen signaling
[27]. This enrichment was stronger in the ER+ MCF7
and T47D cell lines as compared to available ER− breast
cancer, normal breast, and other non-breast cell lines
(Fig. 2c, Additional file 1: Figure S2b, and Add-
itional file 2: Table S4), consistent with an additional
layer of ER-mediated cell-type specificity [27]. Applying
the same enrichment criteria, we also found VIRs to be
enriched in ATAC-seq peaks in the matched cell associ-
ated with active enhancers (H3K27ac and H3K4me1)
and also for H3K4me3, which marks active gene
promoters (Additional file 1: Figure S2c, d and
Additional file 2: Table S6), supporting the notion that
promoters and enhancers cooperatively communicate
through transcriptionally active chromatin [28].
To demonstrate PIR and VIR gene regulatory function,
we assessed the overlap of expression quantitative trait
loci (eQTLs) in normal breast tissue from the Molecular
Taxonomy of Breast Cancer International Consortium
(METABRIC) cohort [2, 29]. We found 800 eQTL genes
(eGenes) with eSNPs (false discovery rate (FDR) < 0.05)
within PIRs in at least 1 analyzed breast cell line. Exam-
ination of the VIR data also revealed 184 eGenes inter-
acting with eSNPs (Fig. 2d). To assess the specificity of
eQTL localization to interacting regions, we maintained
the interaction network by assigning baits to randomly
selected promoters and compared the number of inter-
actions supported by eQTL-target gene pairs. We found
that eQTLs were significantly more likely to loop to
their associated gene than expected by chance, across a
broad range of linear distances from their target pro-
moters (Fig. 2d).
Fine-mapping of VCHi-C and PCHi-C profiles
While the CHiCAGO pipeline is extremely useful for
interaction detection in CHi-C data [23], many of the
generated contact maps contain contiguous restriction
Fig. 2 Promoter-interacting regions (PIRs) are enriched for regulatory features. Heatmaps showing PIR enrichment for a ATAC-seq peaks in breast
cell lines, b histone marks by ChIP-seq in available breast cell lines, and c transcription factor binding in available breast cell lines, expressed as z-
scores. The red outlines highlight key enrichment signals. d The number of interactions between expression single nucleotide polymorphisms
(eSNPs) and associated target genes (observed) compared to randomly assigned interactions (random), binned by interaction distance. Asterisks
represent the significance of enrichment of observed versus randomized interacting regions (permutation test *p < 0.05, **p < 0.01, ***p < 0.001)
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fragments linked with the same target. It is hypothesized
that such collateral contacts might result from inaccur-
acy during the cross-linking process in CHi-C [30] or
from bait migration via Brownian motion [31]. There-
fore, as a complementary interaction scoring method, we
also used a recently developed Bayesian sparse variable
selection approach (“Peaky” [32];). The model proposes
that for any given bait, the expected CHi-C signal at
each prey fragment is expressed as a sum of the contri-
butions from a set of fragments directly contacting that
bait [32]. We applied Peaky to the ~ 1300 baits from the
VCHi-C and ~ 3200 baits from the PCHi-C (Add-
itional file 2: Table S7) to derive a measure of confidence
in the location of a direct contact called the marginal
posterior probability of a contact (MPPC) [32].
To facilitate a comparison with CHiCAGO-scored inter-
actions, we applied an interaction threshold of MPPC ≥
0.1. We filtered for intrachromosomal and interaction dis-
tance ≤ 2Mb and detected ~ 3500 VCHi-C and ~ 7400
PCHi-C interactions per cell type (Additional file 1: Figure
S3a and Additional file 2: Tables S8, S9). For the VCHi-C,
~ 11% of CCV-containing fragments interacted with an
annotated protein- or non-coding promoter, and for the
PCHi-C, ~ 2.5% of promoter fragments specifically inter-
acted with a CCV-containing fragment (Additional file 1:
Figure S3b and Additional file 2: Tables S8, S9). There
were fewer interactions detected by Peaky, perhaps be-
cause Peaky can distinguish and rank a subset of direct
contacts from long stretches of chromatin interactions
[32]. The median linear distance between interactions
from either capture was longer than the CHiCAGO-
scored interactions (ranged from 294 to 489 kb;
Additional file 1: Figure S3c). Similar to the CHiCAGO-
scored interactions, hierarchical clustering based on
MPPC scores also separated the cell lines based on ER sta-
tus (Additional file 1: Figure S3d). We then compared the
CHiCAGO and MPPC scores for each bait-prey pair. As
reported by Eijsbouts et al. [32], we noted that CHiCAGO
and MPPC scores were positively correlated (Add-
itional file 1: Figure S3e; Spearman’s ρ = 0.22–0.37). Peaky
was able to refine the number of CHiCAGO-scored inter-
actions by 12–17% in both captures; however, a propor-
tion of interactions were identified by Peaky but not
CHiCAGO (Additional file 1: Figure S3f). To provide a
more stringent list of CCVs and candidate target genes,
we combined inferences from the two approaches.
Prioritizing CCVs by Peaky fine-mapping of the PCHi-C
data
At many signals, we noted that CHiCAGO identified long
stretches of PIRs, some of which contained CCVs. We
therefore used Peaky to fine-map the CHiCAGO-
identified interactions to identify the likely driver contacts
within these stretches. This approach proved particularly
useful at 9q33.1, where CHiCAGO-identified 24 PIRs
starting at ~ 340 kb from a pregnancy-associated plasma
protein A (PAPPA) promoter (Fig. 3a). Peaky fine-
mapping using a PAPPA promoter bait indicated this
stretch of interactions might be explained by a subset of
contacts (MPPC ≥ 0.1), which spanned 1 (rs811688) out of
29 CCVs in MCF7 cells (Fig. 3a). 3C provided further sup-
port that the HindIII fragment containing rs811688 was
the most frequently interacting fragment with the PAPPA
promoter (Additional file 1: Figure S4a). PAPPA encodes a
secreted zinc metalloproteinase and is an important regu-
latory component of the insulin-like growth factor system
[33]. Recent studies indicate PAPPA is frequently overex-
pressed in luminal B breast tumors [34] and identify
PAPPA as a pregnancy-dependent oncogene that pro-
motes the formation of pregnancy-associated breast can-
cer [35]. Another example is 10q14, where CHiCAGO-
identified 59 PIRs located ~ 1Mb from the GATA binding
protein 3 (GATA3) promoter. Interactions between
GATA3 and CCVs were restricted to the ER+ (T47D and
MCF7) breast cell lines and spanned 49 CCVs (Fig. 3b).
Peaky fine-mapping indicated this stretch of interactions
might be explained by a subset of four contacts, one of
which spanned a region containing CCVs. Two HindIII
fragments within the CCV-containing peak surpassed the
0.1 MPPC interaction threshold and contained 11 out of
the 49 CCVs (Fig. 3b). 3C provided further support that
the HindIII fragment containing 8 CCVs (FragID: 486687)
was the most frequently interacting fragment with the
GATA3 promoter (Additional file 1: Figure S4b). Not-
ably, 1 CCV (rs12765282) within the 3C-identified
peak mapped to a putative regulatory element as de-
fined by H3K27ac marks and TF binding in T47D
cells (Fig. 3c). This CCV is predicted to alter a
GATA3-binding motif, with the risk allele likely act-
ing to decrease GATA3 binding. ChIPseq data
showed that GATA3 and ER bound to the CCV site
in T47D cells, which are homozygous for the protect-
ive g-allele (Fig. 3c, d). GATA3 is important in medi-
ating enhancer accessibility for ER [27], raising the
possibility of a GATA3-mediated regulatory loop
underlying risk at this region.
Taken together, at 77 signals where we could detect at
least 1 promoter-CCV interaction, we could prioritize 839
out of 4208 CCVs using the combined CHICAGO (score
≥ 5) and Peaky (MPPC ≥ 0.1) fine-mapping approach. This
included 33 signals where the number of prioritized genet-
ically indistinguishable CCVs could potentially be reduced
to less than 5 at each signal (Additional file 2: Table S10).
Prioritizing target genes by sequential CHiCAGO and
Peaky fine-mapping
The combined analyses can be extended to integrate,
where possible, the VCHi-C and PCHi-C data.
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Fig. 3 PCHi-C Peaky fine-mapping prioritizes CCVs at 10q14 and 6p22.3. a Chromatin interactions at 9q33.1 in MCF7 breast cancer cells.
Topologically associating domains (TADs; Additional file 2: Table S16) are shown as horizontal gray bars above GENCODE-annotated coding (blue)
and non-coding (green) genes. The PCHi-C bait is depicted as a black box. CCVs are shown as red vertical lines. The ATAC-seq track is shown as a
dark blue histogram. Peaky-defined MPPC values (from PCHi-C BaitID: 479054) are plotted with the prioritized CCV overlaid as a red vertical line.
CHiCAGO-scored interactions are shown as black arcs. The dashed red outline highlights the prioritized CCV rs811688 and the dashed gray
outline the target gene (PAPPA). b Chromatin interactions at 10q14 in T47D breast cancer cells. Topologically associating domains (TADs) are
shown as horizontal gray bars above GENCODE-annotated coding (blue) and non-coding (green) genes. The PCHi-C bait is depicted as a black
box. CCVs are shown as red vertical lines. The ATAC-seq track is shown as a dark blue histogram. Peaky-defined MPPC values (from PCHi-C BaitID:
486406) are plotted with the prioritized CCVs overlaid as red vertical lines. CHiCAGO-scored interactions are shown as black arcs. The dashed red
outline highlights the prioritized CCVs and the dashed gray outline the target gene (GATA3). c Zoomed in view of prioritized CCVs at 10q14.
HindIII fragments are shown as gray bars with their fragment IDs. CCVs are shown as red vertical lines. Black histograms denote ChIP-seq data
from T47D cells for H3K27ac, GATA3, and estrogen receptor (ER; cells treated with DMSO or 17 beta-estradiol (EST)). The dashed gray outline
highlights CCV rs12765282. d Position weight matrix of the GATA3 binding site from JASPAR (red arrowhead indicates the CCV position in the
motif), with homology to the risk (t) and protective (g) alleles of rs12765282 colored below
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One example is 1p22.3, where CHiCAGO-detected in-
teractions in the VCHi-C data between two independent
signals and the LIM-only protein 4 (LMO4) promoter in
Hs578T breast cancer cells (Fig. 4a). Peaky fine-mapping
using signal 2 VCHi-C baits then provided further sup-
port that LMO4 was the likely target gene (Fig. 4a).
Peaky was also applied to signal 1 VCHi-C baits, but the
resulting contact peaks did not reach the 0.1 MPPC
interaction threshold (Additional file 1: Figure S4c). We
then interrogated the PCHi-C data using two LMO4
promoter baits in Hs578T cells. CHiCAGO identified 84
PIRs starting at ~ 612 kb from the LMO4 promoter
(Fig. 4a). Peaky fine-mapping using the same promoter
baits indicated this stretch of interactions might be
Fig. 4 Sequential CHiCAGO and Peaky fine-mapping prioritizes CCVs and target genes. a Chromatin interactions at 1p22.3 in Hs578T breast
cancer cells. Topologically associating domains (TADs) are shown as horizontal gray bars above GENCODE-annotated coding (blue) and non-
coding (green) genes. The VCHi-C or PCHi-C baits are depicted as black boxes. Risk signals 1 and 2 are numbered, and the CCVs within each
signal are shown as colored vertical lines. The ATAC-seq track is shown as a dark blue histogram. Peaky-defined MPPC values (from specified
BaitIDs) are plotted with the prioritized gene overlaid as a dark blue vertical line or prioritized CCVs overlaid as royal blue vertical lines. CHiCAGO-
scored interactions for specified BaitIDs are shown as black arcs. The dashed red outline highlights the prioritized CCVs and the dashed gray
outline the target gene (LMO4). b Zoomed in view of prioritized signal 2 CCVs at 1p22.3. VCHi-C baits are shown as gray bars with their fragment
IDs. CCVs are shown as blue vertical lines. Black histograms denote DNase I hypersensitivity sites or ChIP-seq data for H3K4me1 and CTCF binding
from HMEC cells. The dashed gray outline highlights CCV rs3008455. c Position weight matrix of the CTCF binding site from JASPAR (red
arrowhead indicates the CCV position in the motif), with homology to the risk (g) and protective (a) alleles of rs3008455 colored below. d
Chromatin interactions at 16q24.2 in B80T5 normal breast cells. Topologically associating domains (TADs) are shown as horizontal gray bars above
GENCODE-annotated coding (blue) and non-coding (green) genes. The VCHi-C or PCHi-C baits are depicted as black boxes. CCVs are shown as
red vertical lines. The ATAC-seq track is shown as a dark blue histogram. Peaky-defined MPPC values (from specified BaitIDs) are plotted with the
prioritized genes overlaid as dark blue or green vertical lines and prioritized CCVs overlaid as red vertical lines. CHiCAGO-scored interactions for
specified BaitIDs are shown as black arcs. The dashed red outline highlights the prioritized CCVs and the dashed gray outline the prioritized
target genes (MTHFSD, FOXC2, FOXL1, and FOXC2-AS1)
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explained by a subset of three direct contacts (MPPC ≥
0.1). One contact spanned two HindIII fragments within
signal 2 and potentially prioritized four out of eight
CCVs at this signal (Fig. 4b). Of these, one CCV
(rs3008455) mapped to a putative regulatory element as
defined by open chromatin and TF binding in normal
breast cells (Fig. 4b). This CCV is predicted to alter a
CTCF-binding motif, with the risk allele promoting in-
creased CTCF binding (Fig. 4c). LMO4 is a transcrip-
tional modulator that is overexpressed in > 50% of breast
tumors [36]. Overexpression of LMO4 promotes cell
proliferation, invasion, and tumor formation and induces
mammary hyperplasia in transgenic mice [37].
A more complex example is 16q24.2, where CHi-
CAGO detected 62 VIRs spanning a ~ 320-Kb genomic
region derived from 9 separate VCHi-C baits (Fig. 4d).
Peaky fine-mapping of this VCHi-C data then prioritized
FOXC2, FOXC2-AS1, FOXL1, and MTHFSD as the likely
target genes in B80T5 breast cells (Fig. 4d). We interro-
gated the PCHi-C data using the 4 target gene promoter
baits in B80T5 cells. CHiCAGO identified 40 PIRs span-
ning a ~ 500-Kb genomic region. Peaky fine-mapping
using the same promoter baits indicated this stretch of
interactions might be explained by a subset of 2 direct
contacts (MPPC ≥ 0.1). One contact spanned 5 HindIII
fragments and potentially prioritized 21 out of the pos-
sible 85 CCVs at this signal (Fig. 4d). Preliminary in
silico analyses revealed many of the 21 prioritized CCVs
display regulatory activity, and therefore, additional stud-
ies would be required to determine which are the likely
functional variants. FOXC2 and FOXL1 are members of
the Forkhead family of transcription factors with import-
ant functions in biological processes such as cell cycle
control, proliferation, and development [38]. FOXC2 has
been implicated in triple-negative breast cancer progres-
sion and therapy resistance [39], while FOXL1 is reported
to inhibit breast cancer cell proliferation, invasion, and mi-
gration [40]. Little is known about methenyltetrahydrofo-
late synthetase domain-containing (MTHFSD), but a
recent report suggests the gene encodes a stress granule-
associated RNA-binding protein [41].
Identification of 651 candidate target genes at 139 breast
cancer risk signals
We defined candidate target genes of breast cancer risk
signals by CHiCAGO- and/or Peaky-scored CCV-gene
promoter interactions in VCHi-C or PCHi-C in at least
2 cell lines. This combined analysis resulted in 651 can-
didate target genes at 139 breast cancer risk signals, in-
cluding 419 protein-coding genes (Additional file 2:
Table S11). Most of the identified target genes are
expressed in normal breast tissue, ductal carcinoma in
situ (DCIS), or breast tumors, with 66% of genes differ-
entially expressed between normal breast and breast
tumor (Additional file 2: Table S12) or 33% between
breast organoid and DCIS samples (Additional file 2:
Table S13). The majority of candidate target genes inter-
acted with 1 signal, but ~ 13% interacted with 2 or more
independent signals (Additional file 1: Figure S4d). The
6q25 region is one of the more extreme examples, where
5 out of 6 independent signals all loop to and potentially
regulate ESR1 [42, 43] (Additional file 1: Figure S4e).
More than 80% of signal-target gene interactions
skipped at least 1 annotated gene promoter, and ~ 75%
of signals interacted with at least 2 promoter-containing
fragments (Additional file 1: Figure S4f). One example
that demonstrates both characteristics is 8q24.13, where
signal 1 CCVs interact with 6 candidate target genes
(WDYHV1, FBXO32, CTD-2552 K11.2, ANXA13,
FAM91A1, and TRMT12) including skipping 3 annotated
genes to contact the TRMT12 promoter (Additional file 1:
Figure S4g). Notably, 181 candidate target genes were
identified by both CHiCAGO and Peaky (Additional file 1:
Figure S4 h), which may further prioritize these genes for
functional validation. This priority list includes established
breast cancer driver genes such as MYC and GATA3 [44]
but also includes many genes with no reported role in
breast cancer (Additional file 2: Table S11).
CHi-C identifies TBX3 as the target of multiple risk signals
To further illustrate the power of combining genetic fine-
mapping, CHi-C, and functional studies, we examined in
detail the 12q24 susceptibility region. Genetic fine-mapping
of 12q24 identified at least four independent signals [2, 5]
(listed in Additional file 2: Table S14); signal 1 (seven
CCVs), signal 2 (one CCV), and signal 4 (six CCVs) were
more strongly associated with ER+ tumors, whereas signal
3 (eight CCVs) was associated with both ER+ and ER−
breast cancer (Additional file 2: Table S14). The CCVs in
all four signals are located in a large intergenic region on
12q24 between TBX3 and MED13L (Fig. 5a). We used
ATAC-seq and available ChIP-seq datasets [45, 46] to map
CCVs relative to transcriptional regulatory elements. These
analyses showed evidence of putative regulatory elements
overlapping the CCVs at each signal, indicating that one or
more CCVs likely have high regulatory potential (Fig. 5a).
CHi-C and 3C identified T-Box 3 (TBX3) as the most likely
target gene (Figs. 5a, Additional file 1: Figure S5a, and
Additional file 2: Table S15). Notably, we detected
interactions between TBX3 and each of the four inde-
pendent signals in a cell type-specific manner (Fig. 5a
and Additional file 1: Figure S5b).
Our functional studies focused on the strongest signal
1 CCVs. CRISPRi silencing of the signal 1 element in
ER+ MCF7 cells showed that TBX3, but not TBX5 and
MED13L, levels were significantly reduced (Fig. 5b). Re-
porter assays then confirmed that the element acts as an
enhancer on the TBX3 promoter in the presence of
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either the risk or protective haplotypes (Fig. 5c). We
used available DNase-seq data derived from heterozy-
gous MCF7 cells to show that the risk a-allele of CCV
rs1391721 may promote allele-specific open chromatin
(Fig. 5d). Electrophoretic mobility shift assays (EMSAs)
then assessed TF binding for each of the signal 1 CCVs.
Allele-specific binding by nuclear proteins was observed
for CCVs rs2464264, rs2454399, rs1391721, and
rs1292011 in MCF7 and BT474 extracts (Fig. 5e and
Additional file 1: Figure S6a). Further EMSAs using
competitor DNA against predicted TFs suggested
GATA3 bound to the rs1391721 site (Additional file 1:
Figure S6b). Similar to the 10q14 CCV, rs1391721 is also
predicted to lie in a GATA3 binding site. Here, the risk
a-allele promoted increased GATA3 binding compared
to the protective g-allele (Fig. 5f), as evident in the
GATA3 ChIP-seq data derived from heterozygous
MCF7 cells (Additional file 1: Figure S6c). Two other
TFs involved in estrogen signaling, ESR1 and FOXA1,
also colocalize at this enhancer (Additional file 1: Figure
S6d). To assess occupancy of GATA3 in vivo, we per-
formed ChIP followed by allele-specific qPCR in MCF7
cells and found that GATA3 was preferentially recruited
to the a-allele of rs1391721 (Fig. 5g, h). As further sup-
port, we investigated the correlation between GATA3
and TBX3 expression in the TCGA cohort. A stronger
correlation was observed between GATA3 and TBX3 ex-
pression in normal breasts as compared with the breast
tumor samples (Additional file 1: Figure S6e).
TBX3 is a T-Box TF that has been linked to tumori-
genesis by impacting senescence and apoptosis as well as
promoting proliferation and tumor formation [47]. To
determine whether TBX3 can promote a tumorigenic
phenotype in breast cells, we stably overexpressed or re-
pressed TBX3 in the human mammary epithelial
(HMLE) cell line and the MCF7 breast cancer cell line.
HMLEs have been engineered to express hTERT and the
SV40 large T antigen and can grow in soft agar and form
tumors in immune-deficient mice only upon the intro-
duction of an additional oncogenic insult [48]. Overex-
pression of TBX3 in HMLE cells resulted in a significant
increase in cell colony growth in soft agar, suggesting
that overexpression promotes anchorage-independent
growth (Fig. 6a and Additional file 1: Figure S6f), while
CRISPR/Cas9-mediated TBX3 silencing showed a recip-
rocal effect (Fig. 6b). These results are consistent with
our in vitro data which indicated breast cancer risk was
likely associated with increased TBX3 expression. The
HMLE-TBX3-overexpressing cells were also injected
into the mammary fat pads of nude mice, but no tumors
were observed, suggesting elevated levels of TBX3 alone
is not enough to promote tumor development from
these cells. In contrast, overexpression of TBX3 in
MCF7 cells decreased cell colony growth in soft agar
(Fig. 6c and Additional file 1: Figure S6g), while deple-
tion of TBX3 by targeting dCas9-KRAB to the TBX3
promoter resulted in a significant increase in growth
(Fig. 6d and Additional file 1: Figure S6 h). To further in-
vestigate TBX3 in tumor growth, TBX3-depleted MCF7
cells were injected into the mammary fat pads of nude
mice. Compared to control cells, reduced TBX3 levels
resulted in a marked increase in tumor growth in vivo
(Fig. 6e, f), which was reflected in increased tumor
weights (Fig. 6g). As reported previously [49], these data
suggest that TBX3 can be oncogenic or tumor suppres-
sive depending on the cellular context.
Discussion
The field of 3D chromatin interaction mapping is rapidly
changing how we view the genome and is revealing
(See figure on previous page.)
Fig. 5 Molecular analysis of signal 1 CCVs at 12q24. a Chromatin interactions in MCF7 cells. Topologically associating domains (TADs) are shown
as horizontal gray bars above GENCODE-annotated coding (blue) and non-coding (green) genes. The PCHi-C baits are depicted as black boxes.
Risk signals 1–4 are numbered, and the CCVs within each signal are shown as colored vertical lines. ENCODE ChIP-seq data for available histone
marks are depicted as gray boxes. The ATAC-seq track is shown as a dark blue histogram. ESR1, GATA3, and FOXA1 binding are shown as black
histograms. Peaky defined MPPC values (from PCHi-C BaitID: 596031) are plotted with the prioritized CCVs overlaid as red vertical lines. CHiCAGO-
scored interactions are shown as black arcs. The dashed red outline highlights signal 1 CCVs and the dashed gray outline the target gene (TBX3).
b The 12q24 enhancer was repressed by targeting dCas9-KRAB to the enhancer in MCF7 cells with two different CRISPRi single-guide (sg) RNAs
(SgEnh1 and SgEnh2). PgCON contains a non-targeting control sgRNA. Gene expression of TBX3, TBX5, and MED13L was measured by qPCR and
normalized to GUSB. Error bars represent the SEM (n = 3). p values were determined by two-way ANOVA followed by Dunnett’s multiple-
comparison test (**p < 0.01). c Luciferase reporter assays following transient transfection of MCF7 cells. The 12q24 enhancer containing either the
risk or protective (Prot.) haplotype was cloned into TBX3 promoter-driven luciferase constructs (TBX3 prom). Error bars represent the SEM (n = 3). p
values were determined by two-way ANOVA followed by Dunnett’s multiple-comparison test (**p < 0.01). d Allele-specific DNase I hypersensitivity
at CCV rs1391721 in heterozygous MCF7 cells. The depth of reads containing the risk (red) and protective (blue) alleles are shown. e EMSAs for
signal 1 CCVs to detect allele-specific binding of nuclear proteins. Labeled oligonucleotide duplexes were incubated with MCF7 nuclear extract.
Red arrowheads show the bands of different mobility detected between risk (R) and protective (P) alleles. f Position weight matrix of the GATA3
binding site from JASPAR, with homology to the risk (a) and protective (g) alleles of rs1391721 colored below. g Allele-specific GATA3 ChIP-PCR
results assessed at CCV rs1391721 in heterozygous MCF7 cells. Error bars represent the SEM (n = 3). p values were determined by a two-tailed
Student’s t test (**p < 0.01). h Allelic discrimination plot of the GATA3 ChIP in MCF7 cells. Genomic DNA extracted from homozygous T47D and
Hs578T breast cancer cells were used as controls
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important insights into disease biology. Interpretation of
findings from GWAS has particularly benefited from the
influx of chromatin data, allowing more accurate map-
ping and redefining of candidate causal genes. In this
study, we generated high-resolution chromatin maps in
human breast cells to delineate gene-regulatory interac-
tions between breast cancer CCVs and target genes. We
used two independent algorithms to score chromatin in-
teractions. Peaky assisted the identification of the prob-
able direct contacts from long stretches of CHiCAGO-
identified interactions. This proved useful when examin-
ing PIRs as we were able to further prioritize the list of
CCVs, which will be valuable in future in-depth func-
tional studies. The de-prioritized variants may simply
represent those in linkage disequilibrium with the true
causal variant(s). Similarly, we observed an overlap
between the CHiCAGO- and Peaky-detected target
genes but noted that a proportion was detected by only
one method. This was not unexpected given the differ-
ent statistical models, and further studies will be re-
quired to establish parameters for improved resolution
of direct interactions. Collectively, we could identify 651
candidate target genes at 139 independent breast cancer
risk signals. Of particular interest for post-GWAS func-
tional studies, 65 signals could be prioritized to one or
two candidate target genes (Table 1). Some of the listed
genes already have functional data linking breast cancer
CCVs and somatic point mutations to altered target
gene expression, including ESR1 [42, 43], FGFR2 [50,
51], and MAP3K1 [44, 52].
A recent study used CHi-C to identify 110 putative
target genes at 33 breast cancer risk loci [53].
Fig. 6 Altered TBX3 levels affect breast cell growth and tumor formation. a Representative images of colonies grown in soft agar for HMLE-
control (GFP CON) and HMLE-TBX3-overexpressing cells (TBX3 ORF). The graph depicts the total number of HMLE colonies formed. Error bars
represent SEM (n = 2). b Representative images of colonies grown in soft agar for HMLE-control (PgCON) and HMLE-CRISPR/Cas9 TBX3-edited
cells (SgTBX3-C1/C2). The graph depicts the total number of HMLE colonies formed. Error bars represent SEM (n = 2). c Representative images of
colonies grown in soft agar for MCF7-control (GFP CON) and MCF7-TBX3-overexpressing cells (TBX3 ORF). The graph depicts the total number of
MCF7 colonies formed. Error bars represent SEM (n = 4). d Representative images of colonies grown in soft agar for MCF7-control (PgCON) and
MCF7-dCas9-KRAB TBX3 repressed cells (SgTBX3-P1/P2). The graph depicts the total number of MCF7 colonies formed. Error bars represent SEM
(n = 4). a–d p values were determined by two-way ANOVA followed by Dunnett’s multiple-comparison test (**p < 0.01, ***p < 0.001, ****p <
0.0001). e MCF7-control (PgCON) or MCF7-dCas9-KRAB TBX3-repressed cells (SgTBX3-P1/P2) were injected into the mammary fat pads of nude
mice. Tumor growth curves for each group are shown. Values are shown as average tumor volumes at each time point. Error bars represent SEM
(n = 8–9 mice per group). f Tumors of individual mice were dissected at day 44 post-injection. The five largest tumors of each group are shown.
The scale bar represents 1 cm. g Plot of the individual weights of tumors with mean and SEM shown by cross-bar and errors. e, g Mann-Whitney
U test was used to compare the differences between the groups (*p < 0.05, ****p < 0.0001)
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Surprisingly, only 30 of the 110 genes were also identi-
fied in our study. The lack of concordance may firstly re-
sult from a fundamental difference in capture design;
Baxter et al. were based on SNPs correlated with the
published SNP (r2 ≥ 0.2), whereas the present study cap-
tures only those fragments containing CCVs based on
fine-mapping analysis of a very large association dataset.
In addition, the design used by Baxter and colleagues in-
cluded many examples where oligonucleotide probes
were tiled across large genomic regions rather than re-
stricted to individual HindIII fragments. Baxter et al. also
reported multiple genes as putative targets at some risk
signals, while our analysis of the same signals prioritized
only 1 or 2 genes. For example, at 11p15.5, Baxter et al.
identified 9 target genes, whereas our combined statis-
tical analyses reduced this number to just 2 candidates,
LSP1 and MIR4298.
We acknowledge that some CCV-target gene interac-
tions may have been missed due to intrinsic biases in
the capture. False negatives may result from the lack of
suitable baits for some CCV- and promoter-containing
fragments, short-range contact constraints, or due to the
transient and cell type-specific nature of regulatory chro-
matin interactions. It is also possible that the proportion
Table 1 Independent breast cancer risk signals with ≤ 2 candidate protein-coding genes
Cytoband Locus Signal Target gene/s Cytoband Locus Signal Target gene/s
1p22.3 chr1:87656923_88656923 2 LMO4 8q24.21 chr8:127424659_130041931 3 MYC
1q32.1 chr1:200937832_201937832 1 IPO9 9q31.2 chr9:109803808_111395353 1 KLF4
2p23.3 chr2:28670676_29670676 1 ALK,SPDYA 9q33.1 chr9:118813486_119813486 1 PAPPA
2p24.1 chr2:18815791_19820803 1 OSR1 10p14 chr10:8588113_9588113 1 GATA3
2q35 chr2:217405832_218796508 1 IGFBP5 10q25.2 chr10:114273927_115286154 1 TCF7L2
2q35 chr2:217405832_218796508 3 IGFBP5 10q26.12 chr10:122593901_123849324 2 FGFR2
3p24.1 chr3:26827965_28285247 2 AZI2,CMC1 11p15.5 chr11:1398664_2442575 1 LSP1
3q23 chr3:140612859_141612859 1 ZBTB38 11q13.3 chr11:68831418_69879161 1 MYEOV
4p14 chr4:38312876_39312876 1 TBC1D1,TLR10 11q13.3 chr11:68831418_69879161 2 MYEOV
4q24 chr4:105569013_106856761 1 GSTCD,PPA2 11q13.3 chr11:68831418_69879161 3 MYEOV
5p13.3 chr5:32067732_33067732 1 ZFR 11q24.3 chr11:128952507_129961171 1 BARX2
5p15.33 chr5:779790_1797488 1 SLC6A18 12p11.22 chr12:27639846_29034415 1 CCDC91
5p15.33 chr5:779790_1797488 2 SLC6A18 12p13.1 chr12:13913931_14913931 1 ATF7IP
5q11.1 chr5:49141645_50695093 2 CTD-2203A3.1,ISL1 12q22 chr12:95527759_96527759 1 NTN4,RP11-536G4.1
5q11.2 chr5:55531884_56587883 1 MAP3K1 12q24.21 chr12:115336522_116336522 1 TBX3
5q11.2 chr5:55531884_56587883 4 MAP3K1 12q24.21 chr12:115336522_116336522 2 TBX3
5q11.2 chr5:55531884_56587883 5 MAP3K1 12q24.21 chr12:115336522_116336522 3 TBX3
5q11.2 chr5:57684061_58865569 1 GAPT 13q13.1 chr13:32468810_33472626 1 FRY
5q11.2 chr5:57684061_58865569 2 PDE4D 13q22.1 chr13:73464519_74464519 1 KLF5
5q33.3 chr5:157730013_158744083 1 EBF1 14q13.3 chr14:36632769_37635752 1 SLC25A21,SLC25A21-AS1
6p22.3 chr6:15899557_16899557 1 ATXN1 14q24.1 chr14:68117194_69534682 1 ZFP36L1
6q14.1 chr6:81628386_82795951 1 AL359693.1 14q24.1 chr14:68117194_69534682 2 ZFP36L1
6q23.1 chr6:129849119_130849119 1 AKAP7,TMEM244 16q12.2 chr16:53300954_54355291 2 IRX5,LPCAT2
6q25 chr6:151418856_152937016 2 ESR1 16q23.2 chr16:80148327_81150805 1 CDYL2
6q25 chr6:151418856_152937016 3 SYNE1 18q11.2 chr18:23832476_25075396 1 KCTD1
6q25 chr6:151418856_152937016 5 ESR1 19q12 chr19:29777729_30777729 1 CCNE1
6q25.1 chr6:149086328_150086328 1 TAB2 19q13.31 chr19:43783447_44786513 1 KCNN4
7q22.1 chr7:101054599_102054599 1 COL26A1 20p12.3 chr20:5448227_6448227 1 GPCPD1
7q34 chr7:139442304_140442304 1 SLC37A3 21q21.1 chr21:16073983_17073983 1 HSPA13,NRIP1
8p12 chr8:29009616_30009616 1 DUSP4 21q21.1 chr21:16073983_17073983 2 HSPA13,NRIP1
8q21.11 chr8:75730301_76917937 2 CRISPLD1 22q13.31 chr22:45783297_46783297 1 ATXN10
8q23.3 chr8:116709548_117709548 1 TRPS1 22q13.31 chr22:45783297_46783297 2 ATXN10,WNT7B
8q24.21 chr8:127424659_130041931 2 FAM84B,MYC
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of our observed interactions may be cell culture condi-
tion dependent. It is also important to keep in mind that
interactions between a CCV and gene promoter do not
infer causality. It is likely that correlated CCVs within
some signals have no effect on TF binding or enhancer
activity, or they may act via alternate mechanisms. Con-
sistent with other GWAS follow-up studies [2, 26, 54],
our results support the hypothesis that cis-acting regula-
tory variation is a predominant molecular mechanism at
breast cancer risk signals. However, we saw no CCV-
target gene looping interactions at 57 (out of 196) risk
signals. Twelve signals contained promoter or coding
CCVs, suggesting that direct gene alteration is a prob-
able mechanism underlying these risk associations. The
remaining signals (n = 45) contained baited variant or
promoter fragments, but the lack of detected CCV-gene
interactions suggests mechanisms other than distal regu-
lation. A recent study has incorporated some of the pro-
posed alternate CCV mechanisms together with the
distally regulated genes from this study to generate a
complete catalog of candidate target genes and biological
pathways [5].
We provided functional evidence that breast cancer
risk at 12q24 is driven by the TF, TBX3. TBX3 is over-
expressed in many cancers including breast cancer and
contributes to oncogenesis at multiple levels including
the promotion of proliferation, tumor formation, and
metastasis [47]. Consistent with previous findings, our
in vitro data indicate that the signal 1 CCVs likely act to
increase TBX3 expression through recruitment of
GATA3 to the CCV site, resulting in an increased loop-
ing of the risk CCV-containing enhancer to the TBX3
promoter. Recent studies have suggested that TBX3 may
also function as a tumor suppressor depending on the
cellular context [49]. Indeed, in MCF7 breast cancer
cells, we showed that TBX3 repression promoted colony
formation and in vivo tumor formation. Furthermore,
somatic TBX3 mutations in primary breast tumors are
predominantly loss-of-function through impaired tran-
scriptional repression [55]. Interestingly, a recent report
showed that many of these “double-agent” genes are TFs
and that breast cancer is the second most common can-
cer type associated with dual-function genes [56]. The
molecular mechanisms underlying this duality are largely
unknown, but differing mutation spectrums, interaction
partners, and cellular contexts have been implicated.
Dual-function genes likely contribute to the heterogen-
eity of cancer cells, and some are already considered
promising targets for breast cancer therapy. It will there-
fore be important to refine therapeutic strategies to se-
lectively block one function without compromising the
other.
In summary, we report the most comprehensive study
linking regulatory CCVs to candidate breast cancer
genes. This forms an important resource for the breast
cancer research community that will facilitate the gener-
ation of hypotheses, functional experimentation, and in-
sights into breast cancer biology. We anticipate that
many of the candidate target genes may represent drug
repositioning opportunities or be suitable for future drug
targeting.
Methods
Availability of data and materials
Raw sequencing data has been deposited at EBI:
PRJEB29716. Processed Capture Hi-C data is available
from https://osf.io/2cnw7/. Processed chromatin inter-
action data can be visualized at the Washington Epige-
nome Browser via http://epigenomegateway.wustl.edu/
browser/live/Tei2kygBF. The custom scripts used in the
study are available from https://github.com/jmbeesley/
Beesley_GenomeBiol2019. All datasets and software used
are listed in Additional file 2: Table S16 [5, 12, 16, 23,
25, 32, 45, 46, 57–68].
Cell lines
Estrogen receptor-positive (ER+) breast cancer cell lines
MCF7 and T47D were grown in RPMI medium with
10% (vol/vol) fetal bovine serum (FBS), 1 mM sodium
pyruvate, 10 μg/ml insulin, and 1% (vol/vol) antibiotics.
ER− breast cancer cell lines MDAMB231 and Hs578T
were grown in DMEM medium with 10% (vol/vol) FBS
and 1% (vol/vol) antibiotics. The B80T5 mammary epi-
thelial cell line [69] (provided by Roger Reddel, CMRI,
Australia) was grown in RPMI medium with 10% (vol/
vol) FBS and 1% (vol/vol) antibiotics. The MCF10A
mammary epithelial cell line was grown in DMEM/F12
medium with 5% (vol/vol) horse serum, 10 μg/ml insulin,
0.5 μg/ml hydrocortisone, 20 ng/ml epidermal growth
factor, 100 ng/ml cholera toxin, and 1% (vol/vol) antibi-
otics. Cell lines were maintained under standard condi-
tions (37 °C, 5% CO2), tested for Mycoplasma, and
profiled for short tandem repeats.
Hi-C library preparation
Hi-C libraries were prepared from 4 to 8 × 107 cells per
library (2 biological replicates per cell line; 3 replicates
for the T47D VCHi-C) as described previously [11], but
using in-nucleus ligation as described in [70]. The
immobilized Hi-C libraries were amplified using the Sur-
eSelectXT ILM Indexing pre-capture primers (Agilent
Technologies) with 8 PCR amplification cycles. Each Hi-
C library (750 ng) was hybridized and captured individu-
ally using the SureSelectXT Target Enrichment System
reagents and protocol (Agilent Technologies). After li-
brary enrichment, a post-capture PCR amplification step
was carried out using SureSelectXT ILM Indexing post-
Beesley et al. Genome Biology            (2020) 21:8 Page 13 of 19
capture primers (Agilent Technologies) with 14–16 PCR
amplification cycles.
Biotinylated RNA bait library design
The SureSelectXT Custom Target Enrichment Arrays
were designed using the eARRAY software (Agilent
Technologies). For the VCHi-C, biotinylated 120-mer
RNA baits were designed to both ends of HindIII restric-
tion fragments that contained at least 1 CCV [5]. A total
of 1448 HindIII fragments were captured, covering
6044/7394 CCVs. For the PCHi-C, biotinylated 120-mer
RNA baits were designed to both ends of HindIII restric-
tion fragments that overlapped annotated promoters
within 1Mb of CCVs [5]. A total of 4049 HindIII frag-
ments were captured, overlapping 2298 Ensembl-
annotated promoters (GRCh38) [16]. A bait sequence
was accepted if its GC content was between 25 and 65%,
the sequence contained no more than 2 consecutive nu-
cleotides of the same identity, and was within 330 bp of
the HindIII restriction fragment end. Repetitive elements
were masked using SureDesign masking tools with the
highest level of stringency.
Sequencing of CHi-C libraries
PCHi-C and VCHi-C libraries were sequenced on the
Illumina HiSeq 2500 platform (Kinghorn Centre for
Clinical Genomics, Australia). Two PCHi-C or three
VCHi-C libraries were multiplexed per sequencing lane.
PCHi-C and VCHi-C sequence alignment and data
processing
Raw sequencing reads were truncated, mapped to the
hg19 reference genome, and filtered using the HiCUP
pipeline [62]. Individual library statistics are presented in
Additional file 2: Table S1. Significant interactions were
identified using the CHiCAGO pipeline [23]. For both
captures, replicate libraries for each cell line were ana-
lyzed separately to learn weights which were then used
to merge replicates into a single dataset per cell type. In-
teractions with CHICAGO scores ≥ 5 in at least one cell
type were considered high-confidence interactions.
Principal component and cluster analyses
Principal component analysis (PCA) of the CHiCAGO
interaction scores was performed for both variant and
promoter capture arrays for each individual biological
replicate. Interaction length < 2Mb and CHiCAGO
score > 0 were included. PCA was performed using the
R utility prcomp with unit variance scaling. Hierarchical
clustering with average linkage based on Euclidian dis-
tances was performed on the 1000 interactions with
most variance using R’s heatmap.2 function. Cell types
were clustered based on profiles including interactions
with CHiCAGO score ≥ 5 and length < 2Mb.
Interactions with score ≥ 5 in at least one cell line were
considered.
PCHi-C and VCHi-C concordance
To examine the overall concordance between promoter
and variant captures, we identified interactions common
to both experiments from the full range of CHiCAGO
scores (> 0) for each cell type. The Pearson correlation
between the CHiCAGO scores for interactions from
each of the captures was computed. Interaction scores
for each capture were plotted after inverse hyperbolic
sine (asinh) transformation with Loess-smoothed regres-
sion lines.
Enrichment of genomic features within interacting
regions
Positions of genomic features including DNase-seq
peak, histone modification ChIP-seq peaks, transcrip-
tion factor ChIP-seq peaks (web links provided in
Additional file 2: Table S16), and ATAC-seq peaks
were intersected with PIRs from each cell line. En-
richment was estimated by comparing to a set of
background PIRs generated by maintaining the distri-
bution of interaction distances and interaction counts
relative to promoter baits for each cell type. Interac-
tions were grouped in 50-kb distance bins, and 100
sets of random PIR sets were built for each cell line.
We removed the baited fragments from the pool of
possible PIRs. Z scores were calculated for each gen-
omic annotation (Additional file 2: Tables S4, S5).
Fine-mapping of chromatin contacts
PCHi-C and VCHi-C contact mapping was performed
using the Peaky Bioconductor package [32]. We first
pooled the aligned reads from replicate CHi-C libraries.
Probable interaction-driving contacts were then modeled
for each bait from each cell line independently. We
maintained the default Ω value (5) for each bait. Two
parallel chains were run, and correlation between MPPC
values for interacting prey fragments was tested until r >
0.75 (typically after 206 iterations). We achieved success-
ful convergence for > 93% tested baits. Distributions de-
rived from parallel chains were then merged to generate
cell type- and bait-specific contact maps. An arbitrary
MPPC threshold of 0.1 was used for downstream
analysis.
Expression quantitative trait loci analysis
To determine whether eSNP-target gene pairs were
overrepresented within captured interactions, we
assigned interactions to random promoters within the
same chromosome. This randomization procedure was
repeated 10,000 times. The frequency of eSNP-gene
occurrences within interactions was then tallied in the
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observed interaction set and compared to random
expectation.
ATAC-seq library preparation and data analysis
ATAC-seq was performed as previously described [71].
Briefly, 5 × 104 cells were resuspended in lysis buffer (10
mM Tris-HCl (pH 7.4), 10 mM NaCl, 3 mM MgCl2, and
0.1% (vol/vol) IGEPAL CA-630), then centrifuged at
5000×g for 10 min at 4 °C. Pellets were resuspended in
TD buffer (10 mM Tris (pH 7.6), 5 mM MgCl2, 10%
(vol/vol) dimethylformamide), and 2.5 μl of TDE1 en-
zyme (Illumina). Transposed fragments were purified
using a MinElute PCR purification kit (QIAGEN), then
amplified and indexed with unique library indices using
NEBNext High-Fidelity 2× PCR Master Mix (New Eng-
land BioLabs). PCR products were purified with AMPure
XP beads (Beckman-Coulter) and quantified with a
Qubit dsDNA High-Sensitivity Assay kit (Thermo Fisher
Scientific) and BioAnalyzer High Sensitivity DNA Kit
(Agilent Technologies). Pools of six libraries were se-
quenced per lane on an Illumina HiSeq 2500 (Kinghorn
Centre for Clinical Genomics). Raw sequencing reads
were trimmed for adapter sequences using Cutadapt
(version 1.9 [64];) and aligned using BWA-MEM (ver-
sion 0.7.12 [72];) to the GRCh37 assembly. The aligned
reads were coordinate sorted using Samtools (version
1.1 [65];), and duplicate alignments were marked with
Picard (version 1.129). Qprofiler assessed the sequence
quality and provide fragment length distribution. Peaks
were called for each sample using MACS2 [66]. Peak an-
notation was performed using HOMER [67].
3C validation
3C libraries were generated using HindIII as described
previously [73]. 3C interactions were quantified by real-
time PCR (qPCR) using primers designed within restric-
tion fragments (Additional file 2: Table S15). qPCR was
performed on a RotorGene 6000 using MyTaq HS DNA
polymerase (Bioline) with the addition of 25 μM Syto9,
annealing temperature of 66 °C, and extension time of
30 s. 3C analyses were performed in two independent
3C libraries from each cell line quantified in duplicate.
BAC clones covering each region were used to create
artificial libraries of ligation products to normalize for
PCR efficiency. Data were normalized to the signal from
the BAC clone library and, between cell lines, by refer-
ence to a region within GAPDH.
CRISPR/Cas9 interference and cutting
For CRISPR interference (CRISPRi), the sgRNA targets
(listed in Additional file 2: Table S15), Cas9 binding han-
dle and terminator sequences were synthesized (Inte-
grated DNA Technologies, IDT) and cloned into the
lentiviral vector pgRNA-humanized. Virus-like particles
(VLPs) containing either dCas9-KRAB or a targeting
sgRNA were generated by transfection of HEK293 cells
with Lipofectamine 2000 (Thermo Fisher Scientific).
Cells were cotransfected with the packaging plasmid
pCMV-dR8.91, the VSV-G envelope expression plasmid
pCMV-VSV-G, and with either pHR-SFFV-dCas9-BFP-
KRAB or pgRNA-humanized. VLPs were collected from
culture supernatants, mixed in equal volume, and trans-
duced into MCF7 cells. Cells expressing both mCherry
(via pgRNA-humanized) and blue fluorescent protein
(via dCas9-KRAB) were isolated by FACS on an ARIA
IIIu (Becton-Dickinson). For CRISPR cutting (CRISPRc),
the GFP control and sgRNA targets (listed in Add-
itional file 2: Table S15) were synthesized (IDT) and
cloned into the pXPR_011 lentiviral vector. Virus-like
particles (VLPs) containing the GFP control or targeting
sgRNAs were generated by the transfection of HEK293
cells with FuGene (Promega). VLPs were collected from
culture supernatant, transduced into HMLE-Cas9 cells,
and selected using puromycin for at least 48 h.
Quantitative real-time PCR
Complementary DNA (cDNA) was synthesized from
RNA samples using SuperScript III (Invitrogen). qPCR
was performed using TaqMan assays (Thermo Fisher
Scientific; listed in Additional file 2: Table S15).
Plasmid construction and reporter assays
The TBX3 promoter-driven luciferase construct was
generated by insertion of a PCR-amplified promoter
fragment into the NheI and HindIII sites of the pGL3-
basic vector (primers are listed in Additional file 2: Table
S15). The 12q24 signal 1 enhancer, containing either the
risk or protective CCV alleles, was synthesized as
gBlocks (IDT) and cloned into the BamHI and SalI sites
of the TBX3 promoter construct (coordinates are listed
in Additional file 2: Table S15). Sanger sequencing of all
constructs confirmed variant incorporation. MCF7 cells
were transfected with equimolar amounts of luciferase
reporter plasmids and pRL-TK transfection control plas-
mid with Lipofectamine 3000 (Thermo Fisher Scientific).
Luciferase activity was measured 24 h post-transfection
by the Dual-Glo Luciferase Assay System (Promega). To
correct for any differences in transfection efficiency or
cell lysate preparation, Firefly luciferase activity was nor-
malized to Renilla luciferase activity, and the activity of
each construct was expressed relative to the reference
promoter constructs, which were defined to have an ac-
tivity of 1.
Electromobility shift assays
Gel shift assays were performed with MCF7 or BT474
nuclear lysates and biotinylated oligonucleotide duplexes
(listed in Additional file 2: Table S15). Nuclear lysates
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were prepared using the NE-PER nuclear and cytoplas-
mic extraction reagents (Thermo Fisher Scientific) as
per the manufacturer’s instructions. Total protein con-
centrations in nuclear lysates were determined by Brad-
ford’s method. Duplexes were prepared by combining
sense and antisense oligonucleotides in NEBuffer2 (New
England Biolabs) and heat annealing at 80 °C for 10 min
followed by slow cooling to 25 °C for 1 h. Binding reac-
tions were performed in binding buffer (10% (vol/vol)
glycerol, 20 mM HEPES (pH 7.4), 1 mM DTT, protease
inhibitor cocktail (Roche), and 0.75 μg poly(dI:dC)
(Sigma-Aldrich)) with 7.5 μg of nuclear lysate. For com-
petition assays, binding reactions were pre-incubated
with 1 pmol of competitor duplex (competitor sequences
are listed in Additional file 2: Table S15) at 25 °C for 10
min before the addition of 10 fmol of biotinylated du-
plex and incubation at 25 °C for 15 min. Reactions were
separated on 10% (wt/vol) Tris-Borate-EDTA (TBE)
polyacrylamide gels (Bio-Rad) in TBE buffer at 160 V for
40 min. Duplex-bound complexes were transferred onto
Zeta-Probe positively charged nylon membranes (Bio-
Rad) by semi-dry transfer at 25 V for 20 min, then cross-
linked onto the membranes under 254 nm ultra-violet
light for 10 min. Membranes were processed with the
LightShift Chemiluminescent EMSA kit (Thermo Fisher
Scientific) as per the manufacturer’s instructions.
Chemiluminescent signals were visualized with the C-
DiGit blot scanner (LI-COR).
Chromatin immunoprecipitation
MCF7 cells were cross-linked with 1% (wt/vol) formalde-
hyde at 37 °C for 10 min, rinsed once with ice-cold PBS
containing 5% (wt/vol) BSA and once with PBS, and har-
vested in PBS containing protease inhibitor cocktail
(Roche). Harvested cells were centrifuged for 2 min at
3000 rpm. Cell pellets were resuspended in 0.35 ml of
lysis buffer (1% (wt/vol) SDS, 10 mM EDTA, and 50mM
Tris-HCl (pH 8.1)), protease inhibitor cocktail and soni-
cated three times for 15 s at 70% duty cycle (Branson
SLPt) followed by centrifugation at 13000 rpm for 15
min. Supernatants were collected and diluted in dilution
buffer (1% (wt/vol) Triton X-100, 2 mM EDTA, 150 mM
NaCl, and 20mM Tris-HCl (pH 8.1)). Two micrograms
of anti-GATA3 antibody (Santa Cruz) or control IgG
(Santa Cruz) was prebound for 6 h to protein G Dyna-
beads (Thermo Fisher Scientific) and then added to the
diluted chromatin for overnight immunoprecipitation.
The magnetic bead-chromatin complexes were collected
and washed six times in RIPA buffer (50 mM HEPES
(pH 7.6), 1 mM EDTA, 0.7% (vol/vol) sodium deoxycho-
late, 1% (vol/vol) NP-40, 0.5M LiCl), then twice with TE
buffer. To reverse cross-linking, the magnetic bead com-
plexes were incubated overnight at 65 °C in elution buf-
fer (1% (wt/vol) SDS, 0.1M NaHCO3). DNA fragments
were purified using the QIAquick Spin Kit (QIAGEN).
For qPCR (primers are listed in Additional file 2: Table
S15), 2 μl from a 100-μl immunoprecipitated chromatin
extraction was amplified for 40 cycles. All PCR products
were sequenced by Sanger sequencing.
TBX3 overexpression
The TBX3 overexpression construct (pLX307/TBX3)
was generated by Gateway cloning from pDONR201
containing the full-length TBX3 cDNA into the pLEX_
307 lentiviral destination vector (Thermo Fisher Scien-
tific). A negative control construct (pLX307/CON) was
generated by excising TBX3 via NheI and SpeI restric-
tion enzyme digestion and self-ligating the vector back-
bone. VLPs were generated from HEK293 cells
transfected with pLX307/CON or pLX307/TBX3 as de-
scribed above and transduced into HMLE or MCF7 cells.
Transductants were selected with puromycin for at least
48 h.
Western blotting
Cell pellets were lysed in RIPA buffer (50 mM Tris-HCl
(pH 8.0), 150 mM NaCl; 1% (vol/vol) IGEPAL CA-630,
0.5% (vol/vol) sodium deoxycholate, 0.1% (wt/vol) SDS,
1 mM DTT, protease inhibitor cocktail) and clarified by
centrifugation to remove cell debris. Forty micrograms
of lysate supernatants was separated by SDS-
polyacrylamide gel electrophoresis, electroblotted onto
PVDF membranes by semi-dry transfer (Bio-Rad), and
blocked in blocking buffer (1% (wt/vol) casein, 0.1%
(vol/vol) Tween 20, PBS). TBX3 was detected with 1 μg/
ml rabbit anti-TBX3 antibody (Thermo Fisher Scientific)
and actin with 400 ng/ml of rabbit anti-actin antibody
(Sigma-Aldrich). Primary antibodies were detected with
horseradish peroxidase-conjugated goat anti-rabbit IgG
(Cell Signaling). Detected proteins were visualized with
enhanced chemiluminescence substrate (Bio-Rad) and
the G:BOX Chemi XX6 gel documentation system
(Syngene).
Soft agar colony formation assay
Six-well plates were layered with 0.6% (wt/vol) noble
agar (Becton-Dickinson) in RPMI or DMEM medium
supplemented with 10% (vol/vol) FBS and antibiotics
and allowed to set at 4 °C. Twenty-four hours later, the
cells were trypsinized and 8 × 103 MCF7 or 5 × 104
HMLE cells were resuspended in 0.3% (wt/vol) noble
agar and plated on top of bottom agar layers (three
wells/cell line). Colonies were imaged after 3–4 weeks
using a Leica MZ FLIII stereo microscope. Visible col-
onies > 1 mm in diameter were counted.
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Cell proliferation assay
Cell proliferation was measured using a label-free, non-
invasive cellular confluence assay on the IncuCyte Live-
Cell Imaging System (Essen Bioscience). MCF7 cells
were seeded at 20,000 cells/well into 24-well plates and
imaged on the IncuCyte using a × 10 objective lens every
3 h over 7 days. Imaging was performed in an incubator
maintained at 37 °C under a 5% CO2 atmosphere. Cell
confluence in each well was measured using IncuCyte
ZOOM 2016A software, and the data analyzed using
GraphPad Prism.
Mouse tumor xenograft model
A cholesterol-based pellet containing 17β-estradiol
(0.72 mg, 90-day slow release, Innovative Research of
America) was implanted subcutaneously in the inter-
scapular region of 8-week-old female BALB/c-
Foxn1nu/Arc mice. Three days later, MCF7 CRISPRi-
suppressed cells (1 × 107 cells/mouse) were injected
into the fourth right mammary fat pad (eight to nine
mice per cell line). Tumor volumes were measured
with a digital caliper every second day until the ex-
perimental end stage approved by the QIMR Bergho-
fer animal ethics committee, 525 mm3 according to
the formula (π × length × width2/6).
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